1. Caris Molecular Intelligence®
Table 2. Treatment Associations tested for all solid tumors
Caris Molecular Intelligence®
FoundationOne®
OncoDEEP®
Chemotherapy
Antimetabolites (5-FU, pemetrexed, capecitabine) ✔ ✖
Anthracyclines (doxorubicin, epirubicin, liposomal-doxorubicin)
Alkylating agents (temozolomide, dacrabazine)
Nucleoside analog (gemcitabine)
Platinum agents (cisplatin, carboplatin, oxaliplatin)
Taxanes (docetaxel, paclitaxel)
Topoisomerase inhibitors (Irinotecan, topotecan)
Hormone Therapy
Hormone therapy
Androgen deprivation therapy
Targeted Therapies
ALK inhibitor (crizotinib)
Antiangiogenic agents (bevacizumab)
BRAF inhibitors (vemurafenib, dabrafenib)
EGFR TKIs (erlotinib, gefitinib, afatinib)
HER2-directed therapy (trastuzumab, T-DM1, pertuzumab, lapatinib)
mTOR inhibitors (everolimus, temsirolimus)
Small molecular kinase inhibitor (imatinib)
Immunotherapy
PD-1 inhibitors (nivolumab, pembrolizumab, atezolizumab)
Clinical Trials
Investigational Agents
Jaume Capdevila et al. Molecular Profiling for Clinical Decision Making in Advanced Cancer: A Clinical Appraisal. Journal
of Cancer Research and Treatment, 2017, Vol. 5, No. 3, doi: /jcrt-5-3-1
© The Author(s) Published by Science and Education Publishing.